CompletedNot Applicable

Multi-Drug Resistant Organism (MDRO): Study of Highly Resistant Escherichia Coli

United States300 participantsStarted 2020-11-12

Plain-language summary

This is a prospective, observational, multicenter, case-control study.

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Positive monomicrobial blood culture for 3GCR-Ec (cases) or 3GCS-Ec (control)
✓. Hospitalized at the time of obtaining index blood culture OR in the emergency department at the time of obtaining index blood culture, if followed by hospitalization within 72 hours

✕. Previously included in this study as either control or case subject
✕. Previous blood culture positive for E. coli during the current hospitalization
✕. In vitro non-susceptibility to any carbapenem tested in the local clinical microbiology laboratory
✕. Evidence of carbapenemase production in the E. coli isolate of interest as determined by the local clinical microbiology laboratory

Number of participants who received oral step-down therapy

Timeframe: Within 30 days of culture collection

NCT IDNCT04574596

SponsorDuke University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-06-01